Navigation Links
Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability
Date:2/23/2011

CAMBRIDGE, Mass., Feb. 23, 2011 /PRNewswire/ -- Quanterix Corporation, a single molecule diagnostics company providing technology with unprecedented sensitivity for the life science and in vitro diagnostics markets, today announced the online publication of a study that builds upon the company's Single Molecule Array (SiMoA™) technology by combining digital and analog detection in one straightforward measurement.  The article appears in the journal Analytical Chemistry, and highlights the ability to precisely measure proteins present at not only extremely low levels, but higher concentrations as well, effectively extending the dynamic range of immunoassays from the picomolar level down to sub-femtomolar levels in a single measurement.  

"Many diagnostic applications require tests to be sensitive as well as perform over a broad spectrum of concentrations to allow target analytes to be measured in the majority of clinical samples.  By combining the Quanterix digital approach for single molecule detection with ensemble measurements, we are able to measure proteins over a wider range than either method alone," said David Duffy, Ph.D., corresponding author of the article.

David Okrongly, Ph.D., President and CEO of Quanterix added, "The ability to accurately measure proteins over a larger concentration range, down to sub-femtomolar levels, further moves the company towards our stated goal of providing a universal platform that will improve the quality and clinical value of immunodiagnostics.  This expansion of our SiMoA technology allows us to deliver the most sensitive and precise results without sacrificing assay throughput or increasing cost in the clinical setting."

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix Announces New Technology Evaluation Agreement
2. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
3. Stereotaxis Announces Election of Joseph D. Keegan to Board of Directors
4. China Cord Blood Corporation Announces Results of 2010 Annual General Meeting
5. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
6. Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™
7. Sensus Healthcare Announces the Formation of a Medical Advisory Board
8. Sigma-Aldrich Announces Organizational Changes
9. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
10. MiMedx Announces Launch of AmnioFix™
11. Savient Pharmaceuticals Announces Executive Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
Breaking Biology Technology:
(Date:10/4/2017)... a global clinical research organization (CRO), announces the launch of Shadow, ... 2017. Shadow is designed to assist medical writers and biometrics teams ... European Medicines Agency (EMA) in meeting the requirements for de-identifying clinical ... ... Tom ...
(Date:6/23/2017)... N.Y. , June 23, 2017  IBM (NYSE: ... dairy research, today announced a new collaboration using next-generation ... chances that the global milk supply is impacted by ... Cornell University has become the newest academic institution to ... a food safety initiative that includes IBM Research, Mars, ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
Breaking Biology News(10 mins):